Q4
16.4.2024 14:02:02 CEST | Business Wire | Press release
Q4 Inc. (“Q4” or “the Company”) is redefining investor relations with the IR Ops Platform, delivering a differentiated experience to their clients with seamless workflows and superior insights fueled by secure and private AI. Q4 is the only end-to-end IR Ops Platform designed to empower IR leaders to focus on strategy, building investor relationships, and driving premium valuations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240416587263/en/
AI Earnings Co-Pilot (Photo: Business Wire)
As the first IR Ops Platform, Q4 is eliminating piecemeal IR solutions by utilizing secure AI to create smart workflows that remove tedious administrative tasks that, if mishandled, could significantly impact Investor Relations Officers (“IROs”) and the organization. By leveraging AI, Q4 ensures accurate and efficient completion of these tasks, equipping IR teams with the capacity to focus on their strategic priorities. Gone are the days of disjointed solutions that lack interoperability, each with their tech that leaves IR leaders with incomplete and disconnected data. With a customizable interface based on the world’s largest set of proprietary investor data, everything an IR team needs is now available on a single platform, maximized for efficiency through AI integration.
“Our extensive experience in IR, including our time as a public company, allows us to fully understand the challenges of investor relations and how to overcome them,” said Darrell Heaps, Founder and CEO of Q4. “The IR Ops Platform was purposefully and securely built as an all-in-one solution with AI at the forefront so IR teams can be more efficient, effective, and ultimately help drive premium valuations for their companies.”
The future of IR is here with AI Earnings Co-Pilot, providing AI accelerated earnings preparation by generating tailored first drafts of earnings scripts from past press releases and earnings results without data privacy or security concerns, saving tens of hours of management time during earnings preparation. IROs can unlock new levels of insights from their IR program with the AI Performance Dashboard experience through key peer insights now aggregated in one centralized location, including succinct earnings transcript summaries, news highlights, and stock movements.
Connected data that unifies piecemeal IR solutions provides leading indicators and insights around potential investors, current shareholders, and circling activists so IR teams can take confident action and connect with quality investors. IROs are able to instantly identify recurring participants across their earnings events with unparalleled access to analytics, unveiling new opportunities for engagement and targeted outreach. With simplified earnings lifecycle management, website updates are published 16 times faster than competitors and events boast a 99% platform reliability rate, creating a trusted and intelligent digital destination for investors.
“By creating a single, powerful platform for investor relations, we are increasing the value we provide to our issuer and agency clients, enabling them to successfully implement their IR strategies with unprecedented speed and precision,” remarked Heaps. “We’re proud to be at the forefront of innovation in the IR space and we’re committed to helping IROs thrive.”
As of April 16, 2024, Q4’s IR Ops Platform is available to all Q4 customers and prospects. To learn more or request a demo, please visit www.q4inc.com.
About Q4 Inc.
Q4 Inc. is the first IR Ops Platform with the world’s largest set of proprietary investor data, purpose-built to remove obstacles between public companies and their investors. Q4 gives investor relations leaders and their teams the tools to attract, manage, and understand investors — all in one place. The AI-enabled Q4 IR Ops Platform boasts a simple yet powerful IR website management system, frictionless events software, a robust analytics engine, a streamlined investor CRM, and shareholder intelligence with enhanced metrics to elevate investor targeting strategies. Q4 delivers the data, insights, and workflows that give IR teams the power to focus on what really matters: strategy, relationships, and driving premium valuations for their companies.
The company is a trusted partner to more than 2,600 public companies globally, including many of the most respected brands in the world, and maintains an award winning culture where team members grow and thrive.
Q4 is headquartered in Toronto, with offices in New York and London. Learn more at www.q4inc.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240416587263/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom